Utilization of the over-allotment option in Wilson
Post# of 301275
![Avatar](/images/ProfileImages/1923699486_2723_rssfeed.png)
NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, CANADA, JAPAN OR AUSTRALIA ABG Sundal Collier, Carnegie Investment Bank and DNB Markets (“Joint Global Coordinators and Joint Bookrunners”) have notified Wilson Therapeutics AB (publ) (“Wilson Therapeutics” or the “Company”) that the over-allotment option has been utilized for 371,958 new shares and that stabilization transactions have been carried out. In connection with the offering regarding new shares in Wilson Therapeutics (the “Offering”) and the listing on Nasdaq Stockholm, the Company granted an over -allotment option of 1,277,728 new shares, corresponding to 15 percent of the number of shares in the Offering, in order to cover any over-allotment in connection with the Offering (the “Over-allotment option“). Joint Global Coordinators and Joint Bookrunners have exercised the Over-allotment option for 371,958 new shares. The Company will thereby be provided with additionally approximately SEK 18.2 million, which means that the Company has been provided with approximately SEK 435.6 million in total as a result of the Offering, before issue expenses. Following registration of the new shares issued pursuant to the Over-allotment option, the number of shares and votes in the Company will amount to 25,720,248. The subscription price for the new shares is SEK 49 per share, the same subscription price as in the Offering. Further, Joint Global Coordinators and Joint Bookrunners have carried out stabilization transactions as set out below. All stabilization transactions were carried out between May 12, 2016 and June 10, 2016 in the price interval of SEK 46.70 to SEK 49.00. The stabilization period has now ended and no further stabilization transactions will be carried out. Interval per day +-------------+-------------+ |Date |SEK | +-------------+-------------+ |May 12, 2016 |46.70 - 49.00| +-------------+-------------+ |May 13, 2016 |48.80 - 49.00| +-------------+-------------+ |May 16, 2016 |48.80 - 48.80| +-------------+-------------+ |May 17, 2016 |48.80 - 48.80| +-------------+-------------+ |May 18, 2016 |48.70 - 48.80| +-------------+-------------+ |May 19, 2016 |48.60 - 48.70| +-------------+-------------+ |May 20, 2016 |48.50 - 48.70| +-------------+-------------+ |May 23, 2016 |46.70 - 48.40| +-------------+-------------+ |May 24, 2016 |48.00 - 48.40| +-------------+-------------+ |May 25, 2016 |47.30 - 48.00| +-------------+-------------+ |May 26, 2016 |47.20 - 47.50| +-------------+-------------+ |May 27, 2016 |47.20 - 47.40| +-------------+-------------+ |May 30, 2016 |47.90 - 48.20| +-------------+-------------+ |May 31, 2016 |48.40 - 48.50| +-------------+-------------+ |June 1, 2016 |48.00 - 48.40| +-------------+-------------+ |June 2, 2016 |47.00 - 48.20| +-------------+-------------+ |June 3, 2016 |48.30 - 48.30| +-------------+-------------+ |June 7, 2016 |48.00 - 48.30| +-------------+-------------+ |June 8, 2016 |48.00 - 48.00| +-------------+-------------+ |June 9, 2016 |48.00 - 48.00| +-------------+-------------+ |June 10, 2016|47.00 - 48.00| +-------------+-------------+ All shares in Wilson Therapeutics that Joint Global Coordinators and Joint Bookrunners have borrowed from HealthCap, Abingworth Bioventures, MVM and NeoMed Innovation with the purpose of covering the over-allotment in the listing will thereby be returned within short. About Wilson Therapeutics Wilson Therapeutics is a biopharmaceutical company, based in Stockholm, Sweden, that develops novel therapies for patients with rare diseases such as Wilson Disease. Wilson Therapeutics’ lead product, Decuprate®, is initially being developed as a novel treatment for Wilson Disease and is currently being evaluated in a Phase II clinical study. Wilson Therapeutics is listed in the Mid Cap segment on Nasdaq Stockholm with the stock ticker WTX. Visit www.wilsontherapeutics.com for more information. For further information contact: Jonas Hansson, CEO, Wilson Therapeutics AB Telephone: +46 8 796 00 00 Email: jonas.hansson@wilsontx.eu Wilson Therapeutics AB (publ) Org nr 556893-0357 Västra Trädgårdsgatan 15 SE-111 53 Stockholm The information in the press release is such that Wilson Therapeutics is required to disclose publicly in accordance with the Swedish Securities Market Act. The information was submitted for publication on June 13, 2016 at 8:00 a.m. Important information This announcement is not an offer to sell or a solicitation of any offer to buy any securities issued by Wilson Therapeutics AB (publ) in any jurisdiction where such offer or sale would be unlawful. In any EEA Member State, other than Sweden, that has implemented Directive 2003/71/EC as amended (together with any applicable implementing measures in any member State, the “Prospectus Directive”), this communication is only addressed to and is only directed at qualified investors in that Member State within the meaning of the Prospectus Directive. This document and the information contained herein is not for distribution in or into the United States of America. This document does not constitute an offer to sell, or a solicitation of an offer to purchase, any securities in the United States. Any securities referred to herein have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the “Securities Act”), and may not be offered or sold within the United States absent registration or an applicable exemption from, or in a transaction not subject to, the registration requirements of the Securities Act. There is no intention to register any securities referred to herein in the United States or to make a public offering of the securities in the United States. In the United Kingdom, this document and any other materials in relation to the securities described herein is only being distributed to, and is only directed at, and any investment or investment activity to which this document relates is available only to, and will be engaged in only with, “qualified investors” (as defined in section 86(7) of the Financial Services and Markets Act 2000) and who are (i) persons having professional experience in matters relating to investments who fall within the definition of “investment professionals” in Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the “Order”); or (ii) high net worth entities falling within Article 49(2)(a) to (d) of the Order (all such persons together being referred to as “relevant persons”). In the United Kingdom, any investment or investment activity to which this communication relates is available only to, and will be engaged in only with, relevant persons. Persons who are not relevant persons should not take any action on the basis of this document and should not act or rely on it. Any offering of the securities referred to in this announcement will be made by means of a prospectus. This announcement is not a prospectus for the purposes of the Prospectus Directive. A prospectus prepared in accordance with the Prospectus Directive has been published and is held available at www.wilsontherapeutics.com. Investors should not subscribe for any securities referred to in this announcement except on the basis of information contained in the aforementioned prospectus. Forward-looking statements This communication contains forward-looking statements that reflect the Company’s intentions, beliefs, or current expectations about and targets for the Company’s future results of operations, financial condition, liquidity, performance, prospects, anticipated growth, strategies and opportunities and the markets in which the Company operates, including with respect to prospects for pharmaceutical treatments and studies, including Decuprate®. Forward-looking statements are statements that are not historical facts and may be identified by words such as “believe”, “expect”, “anticipate”, “intend”, “may”, “plan”, “estimate”, “will”, “should”, “could”, “aim” or “might”, or, in each case, their negative, or similar expressions. The forward-looking statements in this release are based upon various assumptions, many of which are based, in turn, upon further assumptions. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, it can give no assurances that they will materialize or prove to be correct. Because these statements are based on assumptions or estimates and are subject to risks and uncertainties, the actual results or outcome could differ materially from those set out in the forward-looking statements as a result of many factors. Such risks, uncertainties, contingencies and other important factors could cause actual events to differ materially from the expectations expressed or implied in this release by such forward-looking statements. The Company does not guarantee that the assumptions underlying the forward-looking statements in this presentation are free from errors nor does it accept any responsibility for the future accuracy of the opinions expressed in this presentation or any obligation to update or revise the statements in this presentation to reflect subsequent events. Undue reliance should not be placed on the forward-looking statements in this document. The information, opinions and forward-looking statements contained in this communication speak only as at its date and are subject to change without notice. The Company does not undertake any obligation to review, update, confirm or to release publicly any revisions to any forward-looking statements to reflect events that occur or circumstances that arise in relation to the content of this communication.
![Like This Post](/images/thumb-up.png)
![Dislike This Post](/images/thumb-down.png)